The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Rayvow



Eli Lilly Nederland B.V.EU/1/21/1587/011-020

Main Information

Trade NameRayvow
Active SubstancesLasmiditan Succinate
Dosage FormFilm-coated tablet
Licence HolderEli Lilly Nederland B.V.
Licence NumberEU/1/21/1587/011-020

Group Information

ATC CodeN02CC Selective serotonin (5HT1) agonists
N02CC08 Lasmiditan

Status

License statusAuthorised
Licence Issued17/08/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back